-
[The “In China for Global”] approach not only ensures that we can provide effective treat-ments to Chinese patients but also unlocks the full potential of our drugs for a global au-dience.
September 11, 2024 -
New Gene Therapy Shows Potential for Safety, Efficacy in Mouse Model
May 11, 2022 -
China Biotech CEO Podcast: CANbridge’s Xue On Orphan Drug Coverage, Financing, Gene Therapy
27 Apr 2022
-
CANbridge Announces the First Prescription of Gaurunning®, a Class 1 New Drug for Treating Type I and III Gaucher Disease
CANbridge Announces the First Prescription of Gaurunning®, a Class 1 New Drug for Treating Type I and III Gaucher Disease -
CANbridge Announces Marketing Approval of Velaglucerase-beta for Injection (Gaurunning), a Class 1 New Drug for Treating Type I and III Gaucher Disease, in China
CANbridge Announces Marketing Approval of Velaglucerase-beta for Injection (Gaurunning), a Class 1 New Drug for Treating Type I and III Gaucher Disease, in China -
CANbridge Announces that Velaglucerase-beta for Injection Successfully Passed the Pre-approval inspection and Pre - marketing GMP Compliance Inpection for the Pilot Biological Product of Divided manufacturing
CANbridge Announces that Velaglucerase-beta for Injection Successfully Passed the Pre-approval inspection and Pre - marketing GMP Compliance Inpection for the Pilot Biological Product of Divided manufacturing -
CANbridge Announces Expansion of Livmarli® Label to Include ALGS Patients as Young as 2 Months in Taiwan
CANbridge Announces Expansion of Livmarli® Label to Include ALGS Patients as Young as 2 Months in Taiwan -
CANbridge Announces Marketing Approval of Livmarli® in Taiwan for the Treatment of Cholestatic Pruritus in PFIC Patients
CANbridge Announces Marketing Approval of Livmarli® in Taiwan for the Treatment of Cholestatic Pruritus in PFIC Patients -
CANbridge and Scriptr Global Announce Publication in the Journal Science Reporting the Discovery of the StitchR™ RNA Assembly Technology and its Application for the Treatment of Muscular Dystrophies
CANbridge and Scriptr Global Announce Publication in the Journal Science Reporting the Discovery of the StitchR™ RNA Assembly Technology and its Application for the Treatment of Muscular Dystrophies -
CANbridge Pharmaceuticals CAN103 New Drug Application (NDA), for Gaucher disease, Accepted by China’s National Medical Products Administration
CANbridge Pharmaceuticals CAN103 New Drug Application (NDA), for Gaucher disease, Accepted by China’s National Medical Products Administration -
CANbridge Pharmaceuticals Successfully Obtains Drug Manufacturing License Type B Certificate
20241028 -
CANbridge Pharmaceuticals’ CAN103 for Gaucher Disease Granted Priority Review Status by CDE of the NMPA
20240930